Swiss National Bank’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Swiss National Bank’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-31,092	Closed	-$375K	–	2582
2019 Q1	$375K	Hold	31,092	–	–	﹤0.01%	2429
2018 Q4	$390K	Buy	31,092 +4,600	+17%	+$63.5K	﹤0.01%	2428
2018 Q3	$393K	Hold	26,492	–	–	﹤0.01%	2453
2018 Q2	$446K	Hold	26,492	–	–	﹤0.01%	2466
2018 Q1	$607K	Sell	26,492 -1,300	-5%	-$28.9K	﹤0.01%	2313
2017 Q4	$719K	Hold	27,792	–	–	﹤0.01%	2271
2017 Q3	$410K	Hold	27,792	–	–	﹤0.01%	2425
2017 Q2	$388K	Hold	27,792	–	–	﹤0.01%	2474
2017 Q1	$474K	Hold	27,792	–	–	﹤0.01%	2392
2016 Q4	$286K	Hold	27,792	–	–	﹤0.01%	2521
2016 Q3	$281K	Hold	27,792	–	–	﹤0.01%	2495
2016 Q2	$312K	Buy	27,792 +1,500	+6%	+$19.1K	﹤0.01%	2512
2016 Q1	$348K	Buy	26,292 +11,292	+75%	+$163K	﹤0.01%	2450
2015 Q4	$285K	Buy	+15,000	New	+$326K	﹤0.01%	2504

Other funds holding CNCE

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Swiss National Bank's CNCE Position: Q2 2019 in Review

Swiss National Bank sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2019, closing a stake of 31,092 shares — an estimated $375K sold.

Swiss National Bank first reported a position in CNCE in Q4 2015 and held it in 14 quarters. The position peaked at $719K in Q4 2017. 87 funds tracked by Wall St. Rank hold CNCE as of Q2 2019.

Swiss National Bank reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Swiss National Bank sold 31,092 Concert Pharmaceuticals, Inc. shares in Q2 2019, an estimated $375K.
Swiss National Bank first reported a position in Concert Pharmaceuticals, Inc. in Q4 2015 and held it in 14 quarters.
Swiss National Bank's Concert Pharmaceuticals, Inc. position peaked at $719K in Q4 2017.
87 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2019.

Based on Swiss National Bank's 13F filing for Q2 2019, filed 2 Aug 2019.